TOBACCO VANGUARD, est. 1977
Not for all and sundry.
VALUE REASSERTED
By M. Reuven
There comes a point in every market cycle when price catches up with truth. Not the truth of narrative or fashion, but the quiet arithmetic of yield, compounding, and return. We are, by all appearances, approaching such a moment once again.
For over a decade, Philip Morris International has been the darling of modern tobacco investors. It promised secular growth through reduced-risk products, expansion into smoke-free markets, and a forward-facing brand that would, supposedly, transcend the industry’s decline. In exchange, investors accepted a premium valuation and a lower yield, reassured, perhaps, by the language of innovation and regulatory leadership. British American Tobacco, by contrast, was treated as yesterday’s firm: unfashionable, overleveraged, and heavily reliant on combustible volumes in low-growth markets.
Yet capital, unlike commentary, is not sentimental.
Since the beginning of 2024, British American Tobacco’s ADR (BTI) has returned 76.6% on a price-only basis. Philip Morris International (PMI) has returned 70.6% over the same period. These figures are close. But when dividends are considered, the picture changes entirely. BTI now yields over 6%, while PMI yields around 3.4%. The effect is cumulative. The total return gap widens to over 10 percentage points, a vast gulf in financial terms, particularly for two firms in the same sector, operating under comparable macro conditions.
The reasons are not mysterious. BAT’s management has quietly deleveraged the balance sheet, stabilised U.S. combustibles, and scaled back RRP spending to favour profitability over posturing. PMI, meanwhile, has continued its expensive transformation, purchasing Swedish Match, absorbing ZYN’s growth into its valuation, and navigating an ever-complex global regulatory framework with a more modest shareholder payout. The result is a tale of two philosophies: one rooted in cash flow and return, the other in strategy and hope.
Tobacco Vanguard holds no brief for corporate sentimentalism. We assess value where it arises, not where it is spoken of. The re-rating of BTI is a reassertion of discipline over narrative. Its outperformance is not a speculative anomaly but a repricing of tangible reality: more yield, more return, more solvency.
Indeed, it may be said that the market is not so much endorsing British American Tobacco as it is ceasing to pretend otherwise. For years, the discount was irrational. Now it is merely narrowing. The recovery of BTI is not a trade, but a restoration.
And if we are to speak in philosophical terms, because this publication always will, then we might say the following: the age of promise is yielding to the age of proof. The investor, grown weary of growth stories and platform valuations, seeks now the comfort of margins, of dividends, of arithmetic.
In this light, the story of British American Tobacco is not a redemption. It is a return. A return to value, to discipline, to the facts of economic life. The sort of return that does not make headlines, but does, in time, build fortunes.
For the avoidance of doubt, Tobacco Vanguard has never accepted payment from any tobacco firm, and never shall. We write as observers, not apologists. All financial data as of 30 July 2025.
#TobaccoStocks #ValueInvesting #Dividends #BritishAmericanTobacco #PhilipMorris #TotalReturn #IncomeInvesting #EquityValuation #CashFlow #MarketDiscipline #YieldMatters #InvestorReturns #CapitalPreservation #BATS #BTI $BATS $BTI